The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes

New Insights Into Molecular Mechanisms of Diabetic Kidney Disease

(2014) Shawn S. Badal et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat

(2014) Peter Ochodnicky et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

Change in Albuminuria and eGFR Following Insulin Sensitization Therapy Versus Insulin Provision Therapy in the BARI 2D Study

(2013) P. August et al.   Clinical Journal of the American Society of Nephrology

Metabolic syndrome and chronic kidney disease

(2013) Ajay K. Singh et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

PPARγ signaling and metabolism: the good, the bad and the future

(2013) Maryam Ahmadian et al.   NATURE MEDICINE

Peroxisome Proliferator-Activated Receptor   Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes: Evidence from meta-analysis of 18 studies

(2012) H. Zhang et al.   DIABETES CARE

Comment on: Zhang et al. Peroxisome Proliferator-Activated Receptor   Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes: Evidence From Meta-Analysis of 18 Studies. Diabetes Care 2012;35:1388-1393

(2012) E. Lapice et al.   DIABETES CARE

Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease

(2011) Paul Williams et al.   BMC Medical Genetics

PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases

(2011) Jichun Yang et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

PPAR 2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies

(2011) S. De Cosmo et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The Association Between the Peroxisome Proliferator-Activated Receptor-γ2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes Mellitus: A HuGE Review and Meta-Analysis

(2010) Hebe N. Gouda et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

PPAR-γ Agonism for Cardiovascular and Renal Protection

(2010) Pantelis A. Sarafidis et al.   Cardiovascular Therapeutics

Pro12Ala Polymorphism in the PPARG Gene Contributes to the Development of Diabetic Nephropathy in Chinese Type 2 Diabetic Patients: Comment on the study by Liu et al.

(2010) E. Lapice et al.   DIABETES CARE

Impact of the PPAR -γ 2 Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT

(2009) Salvatore De Cosmo et al.   DIABETES

Pro12Ala Polymorphism in the PPARG Gene Contributes to the Development of Diabetic Nephropathy in Chinese Type 2 Diabetic Patients

(2009) L. Liu et al.   DIABETES CARE

The PPARγ2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy

(2008) A. Jorsal et al.   MOLECULAR GENETICS AND METABOLISM

Adipose tissue-specific PPARγ deficiency increases resistance to oxidative stress

(2007) Weijia Luo et al.   EXPERIMENTAL GERONTOLOGY